ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 605

Childhood Lupus Nephritis: Long Term Outcome Of 91biopsy Proven Cases From India

Puja Srivastava1, Bonnie Abujam2, Ramnath Misra1, Able Lawrence1, Vikas Agarwal1 and Amita Aggarwal1, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Postgraduate Institute of Medical Education and Research, Chandigarh, India

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cyclophosphamide and infection, Kidney, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Childhood SLE has a higher prevalence of lupus nephritis (LN) as well as proliferative LN than adults. There is ethnic variation in response to treatment as well as outcome of LN. There is limited data on long-term outcome of Childhood LN from Indian subcontinent. 

Methods: Retrospective analysis of case records of patients of SLE over last 24 years was done. The inclusion criteria were: fulfillment of ACR 1987 criteria for diagnosis, age of onset less than 18 years, biopsy proven lupus nephritis. Data on clinical features, treatment, outcome, complications and mortality was collected.  

Results: Among 1015 patients with SLE there were 206 patients with childhood onset SLE. Among these 206 patients 145 had some evidence of renal disease of which 93 underwent biopsy (2 were inadequate) thus data on 91 patients was analyzed.

Among these 91 children (82 girls), the mean age at onset was 13.7+ 3.5 years and the median duration of disease at presentation was 1 year. LN was present at onset in 76 patients.

Proteinuria was present in 92% (18% nephrotic range), hematuria in 75%, leucocyturia in 75% and 11% had cellular casts.  19 patients had raised serum creatinine at presentation.  The distribution of histological classes was (class I: 1, class II:13 , Class III: 24, Class IV: 41, Class V: 12 patients).  Eight patients had associated membranous nephropathy along with proliferative GN. Out of these 63 received Cyclophosphamide and 5 received MMF as induction therapy.

The median follow up was 8 (0.1-23) years. Only 12 had less than 1 year follow up and 22 patients had more than 10 year follow up.  At the last follow up 58 were in complete renal remission, 19 had partial remission, 5 had active renal disease, 3 had ESRD and 6 had died (one each due to staph sepsis, pancreatitis, disseminated TB, stroke, ESRD, unknown). 31 patients had infection of which 14 required hospitalization. 44 patients had major disease flare and 15 had minor flare.

The 5 year actuarial survival   was 95% and the 10 year survival was 88%. Histological class had no effect on survival even though all deaths occurred in patients with proliferative LN.  There was no effect of gender or age of onset.

 

Conclusion: Proliferative GN is the most common renal pathology. Almost two third patients are in complete remission at a median follow up of 7 years. 10% of children either died or had ESRD. The outcome is comparable to the Western data however the infection rate is higher.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Disclosure:

P. Srivastava,
None;

B. Abujam,
None;

R. Misra,
None;

A. Lawrence,
None;

V. Agarwal,
None;

A. Aggarwal,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/childhood-lupus-nephritis-long-term-outcome-of-91biopsy-proven-cases-from-india/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology